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We would like to draw to point out that sometimes even
the genetic diagnosis can be misleading. We have recently
reported the results of biochemical and sequence analysis
with quantification, by real-time PCR, of alternatively spliced
GLA mRNAs in five male Fabry patients.2 In this study, the
standard genomic DNA protocols based on sequencing
analysis failed to identify any mutation in a 62-year-old
male patient with a very low a-galactosidase A activity and a
classical Fabry disease phenotype. Also in his 64-year-old
sister, who suffered since youth from acroparesthesias and
abdominal pain but presented with an a-galactosidase A
activity within the normal range, the standard genomic DNA
analysis did not identify any mutation.
Because of this singular condition, studies on GLA
mRNAs on the patient’s fibroblasts using absolute real-time
RT-PCR quantification were carried out. An impressive
reduction in predominant lysosomal GLA transcripts was
detected; in contrast the alternatively spliced GLA mRNAs
were dramatically overexpressed, suggesting a transcription
regulation defect. The subsequent mRNAs sequence analysis
showed the absence of any reported mutation; genomic DNA
sequence analysis identified a new intronic mutation,
g.9273C4T, located 5 nucleotides upstream of the alternative
30 splicing junction. This genetic lesion, absent in the
normal population, was also identified in the patient’s
affected sister. These findings strongly suggest a correlation
between the new intronic mutation and the unbalanced
a-galactosidase A mRNAs ratio, which could therefore
be responsible for the reduced enzyme activity that
causes the Fabry disease. For these reasons, the recognition
of the g.9273C4T nucleotide change prompted us to
start enzyme replacement therapy (ERT) also in the affected
sister.
Our patient with the classic form of the disease and the six
patients with cardiac forms reported by Ishii et al.3 clearly
showed that alteration in synthesis or processing of the GLA
mRNAs is more frequent than expected. On the basis of such
considerations, and taking advantage of real time RT-PCR
analysis we recently developed, we argue that studies at the
transcriptome level should be included in the routine
molecular investigation when DNA standard protocols fail
to identify any genetic lesion.
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We thank Drs Mignani and Morrone for their comments
and for highlighting a role for real-time PCR in diagnosing
Fabry disease.1 However, as this method involves a skin
biopsy to obtain mRNA, we would suggest limiting this
approach to suspected Fabry patients in whom no
mutation is obtained by genomic DNA screening of the
a-galactosidase A (GALA) gene. Further, to maximize the
detection level from the genomic DNA screen it would
seem helpful to include the alternative exon and flanking
intronic regions in this analysis to identify some of the
variants highlighted by Filoni et al.2
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To the Editor: Finkelstein’s paper1 emphasizes ‘major
deficits’ in kidney patients’ perceived knowledge. However,
developing service-led education programs will not ensure
informed, activated patients.2 In the United Kingdom,
educational information provided by services was difficult
to understand, incomplete, and designed for the wrong
purpose.3 An awareness of the evidence from guidelines on
designing good-quality written information4 and the science
underpinning patients’ behavior and decision making is
missing from this educational information. Different types of
information structured in different ways are required for
different purposes; information to prepare patients for
vascular access surgery requires a different approach than
information enabling patients’ decisions about dialysis.
Facilitating informed, activated patients requires several
steps:5 patients need to be alerted to a decision they have
responsibility for; full information needs to be presented
without bias; patients need support to assimilate facts with
their existing values; patients need to make the decision based
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on these evaluations. Nephrologists do not need to know how
these steps are met, but they do need to know how to
collaborate with non-clinical experts, such as psychologists,
to develop effective information interventions; psychologists’
expertise is in understanding how people think and behave.
Finkelstein’s paper proposes a challenge for nephrologists to
enhance the education of their patients. The challenge,
however, may be to develop a willingness on nephrologists’
part to be educated by expert non-clinicians.
1. Finkelstein FO, Story K, Firanek C et al. Perceived knowledge
for patients cared for by nephrologists about chronic kidney
disease and end stage renal disease therapies. Kidney Int 2008; 74:
1178–1184.
2. Fox C, Kohn LS. The importance of patient education in the treatment of
chronic kidney disease. Kidney Int 2008; 74: 1114–1115.
3. Winterbottom A, Bekker HL, Conner M et al. Evaluating the quality of
patient information provided by renal units across the UK. Nephrol Dial
Transplant 2007; 22: 2291–2296.
4. Ley P, Llewelyn S. Chapter 5: Improving patients’ understanding recall,
satisfaction and compliance. In: Broome A, Llewelyn S (eds). Health
Psychology: Processes and Applications. 2nd edn. Chapman and Hall:
London, 1995.
5. Bekker HL, Hewison J, Thornton JG. Understanding why decision
aids work: linking process and outcome. Patient Educ Couns 2003; 50:
323–329.
Andrew F. Mooney1, Anna Winterbottom2 and Hilary L Bekker3
1Renal Unit, St James’s University Hospital, Leeds, UK; 2Leeds Institute
of Psychological Sciences, University of Leeds, Leeds, UK and 3Leeds Institute
of Health Sciences – School of Medicine, University of Leeds, Leeds,
United Kingdom
Correspondence: Andrew F. Mooney, Consultant Renal Physician,
St James’s University Hospital, Leeds LS9 7TF, UK.
E-mail: andrew.mooney@leedsth.nhs.uk
Response to ‘The importance of
expert education in enabling
informed, activated patients’
Kidney International (2009) 75, 1117; doi:10.1038/ki.2009.37
The letter by Mooney et al.1 concerning our article2
emphasizes the challenges facing nephrologists in terms of
providing education for patients with chronic kidney
disease (CKD). His points are indeed very well taken.
There needs to be a complete re-examination of how
education is provided to CKD patients. Psychologists and
educators need to be recruited to assist in the development
of these education programs. Clinical staff, including
nephrologists, nurses, dieticians, social workers, and
clerical personnel, need to be recruited to learn more
effective communication skills to provide education to
patients of varying educational and ethnic backgrounds.
As pointed out by Mooney et al., the ‘science underpinning
patients’ behavior and decision making’ needs to be
critically studied and examined in the context of patient
outcomes and perceived knowledge. These challenges are
made all the more difficult because of the complex medical
problems of the patients and the particular challenges
presented in dealing with the cognitive and psychosocial
problems of CKD patients.
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To the Editor: I read the interesting article by Schileper et al.1
The authors stated that the vascular access calcification can
predict mortality among dialysis patients. In Table 4 of this
article, the authors described how age, high-sensitive
C-reactive protein, carotid intima media thickness, and
iliacal calcification were significant predictors for mortality
by a univariate Cox regression model. However, in Table 3 of
this article, they reported multivariate Cox regression results
by adjusting for age, diabetes mellitus, dialysis vintage, Kt/V,
and presence of vascular disease by entry method.
I don’t agree with their ignoring those significant
predictors of mortality by using the entry method because
carotid intima media thickness, iliacal calcification, and
C-reactive protein were reported to be associated with
patients’ mortality.2–4 If they adjusted these three factors by
forward or backward methods in a Cox regression model,5
the results are likely to have been significantly different. The
vascular access calcification might have been non-significant
in this model. If this happened, the vascular access
calcification would have been called an intermediate factor
from the point of view of epidemiology.
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